VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
OCULOcular Therapeutix, Inc.
$9.43$2.1B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksOCULEarnings History

OCUL logoOcular Therapeutix, Inc. (OCUL) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$290M
● Net Loss
TTM EPS (Diluted)
$-1.30
Per share, diluted
YoY EPS Growth
-16.4%
Declining
Net Margin
-513.2%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-521.0%
Gross Margin87.3%
Return on Equity-54.9%
Return on Assets-42.0%
Record Annual Net Income-$7MFY2021
Record Quarterly EPS$-0.17Q3 2020
Consecutive Profitable Years0years
Q1 2026
Net Income-$89M
EPS (Diluted)$-0.40
YoY Growth-16.4%Declining
QoQ Growth-37.1%Declining

Loading earnings history...

Ocular Therapeutix, Inc. (OCUL) Earnings Overview

As of June 22, 2026, Ocular Therapeutix, Inc. (OCUL) reported trailing twelve-month net income of -$290M, reflecting -16.4% year-over-year growth. The company earned $-1.30 per diluted share over the past four quarters, with a net profit margin of -513.2%.

Looking at the long-term picture, OCUL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2021.

Ocular Therapeutix, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including RCKT (-$209M net income), KALA (-$20M net income), ALDX (-$27M net income), OCUL has comparable earnings metrics. Compare OCUL vs RCKT →

OCUL Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
OCUL logoOCULCurrent
-$290M$-1.30-513.2%-54.9%-16.4%—
RCKT logoRCKT
-$209M$-1.87--60.3%+26.4%
KALA logoKALA
-$20M$-2.41--279.2%+52.6%
ALDX logoALDX
-$27M$-0.45--58.7%+40.4%
NVCR logoNVCR
-$173M$-1.52-20.8%-38.9%+21.8%
SGHT logoSGHT
-$37M$-0.69-49.7%-50.7%+28.2%
Best in group
Lowest in group

OCUL Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$266M-37.4%-$270M$-1.42-513.2%-521.0%
2024-$194M-139.7%-$172M$-1.22-303.7%-269.6%
2023-$81M-13.7%-$82M$-1.02-138.1%-141.0%
2022-$71M-984.1%-$79M$-0.97-138.0%-152.7%
2021-$7M+95.8%-$78M$-0.98-15.1%-179.3%
2020-$156M-80.2%-$63M$-2.56-894.3%-361.1%
2019-$86M-49.7%-$86M$-1.91-2043.3%-2029.9%
2018-$58M+9.0%-$59M$-1.57-2899.1%-2970.8%
2017-$63M-41.8%-$62M$-2.20-3296.2%-3220.1%
2016-$45M-12.5%-$43M$-1.80-2369.0%-2296.0%
2015-$40M-38.7%-$38M$-1.71-2271.3%-2182.7%
2014-$29M-115.1%-$27M$-2.69-3710.9%-3509.6%
2013-$13M+5.5%-$13M$-4.52--
2012-$14M--$14M$-4.78-140930.0%-136710.0%

Download Data

Export OCUL earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

OCUL — Frequently Asked Questions

Quick answers to the most common questions about buying OCUL stock.

What is OCUL earnings per share (EPS)?

OCUL trailing twelve-month (TTM) diluted EPS is $-1.30, reflecting -16.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Ocular Therapeutix, Inc.'s net income?

Ocular Therapeutix, Inc. (OCUL) trailing twelve-month net income is $-290M as of 2025. Earnings declined -16.4% year-over-year.

Is OCUL profitable?

OCUL is not currently profitable on a TTM basis, reporting a net loss of $-290M. Net margin is -513.2%. Investors should monitor for a return to profitability.

What is OCUL's earnings growth rate?

OCUL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are OCUL's profit margins?

Ocular Therapeutix, Inc. net profit margin is -513.2%, operating margin is -521.0%, and gross margin is +87.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -54.9%.

Is OCUL growing earnings?

OCUL earnings are declining — EPS fell -16.4% year-over-year. TTM net income dropped to $-290M. This contrasts with the 5-year CAGR of N/A.

What was OCUL's best earnings year?

Ocular Therapeutix, Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2021. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were OCUL's earnings last quarter?

OCUL's most recent reported quarter was Q1 2026. Net income was $-89M with diluted EPS of $-0.40. For a full breakdown of all quarters, see the quarterly earnings table on this page.

OCUL Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view